Jonathan Gelfond

Professor

University of Texas Health Science Center at San Antonio
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (11)

Statistical analysis of detected N-glycans in each category of TMA. A, PCA score plot of all 152 N-glycans. B, PLS-DA plot and corresponding importance feature plot. C, t test plot of NED vs. MET with structures shown for the top 10 most significant peaks. D, Pattern search graph showing the top 25 peaks correlated with 2905.0368 (Hex8dHex1HexNAc7), m / z values of N-glycans with at least one or more fucose shown in red boxes. VIP, variable importance in projection.

Year:

2025

Analysis of collagen/ECM profile of NED vs. MET cohort from data obtained by LC-MS/MS. A, Pie chart representations of abundance (peak intensity and number of peptides identified via LC-MS/MS) of all detected protein species within the MET cohort. B, Pie chart representations of abundance of all detected protein species within the NED cohort.

Year:

2025

Statistical analysis of detected N-glycans in each category of TMA following EndoF3 and PNGaseF digestion. A, t test plot of detected N-glycans following EndoF3 digestion. Structures shown for top 10 most significant N-glycans ( B ) t test plot of detected N-glycans following PNGaseF digestion. Structures shown for top 10 most significant N-glycans C, Left-Right: PCA, PLS-DA plots for detected N-glycans following EndoF3 digestion. ROC curve showing NED vs. MET after EndoF3 digestion D, Left-Right: PCA, PLS-DA plots for detected N-glycans following PNGaseF digestion. ROC curve showing NED vs. Mets after PNGaseF digestion.

Year:

2025

Prostate cancer is a significant health concern, with metastasis posing major clinical challenges and resulting in poor patient outcome. Despite screening and treatment advances, a critical need for novel biomarkers to predict prostate cancer progression at the time of prostatectomy persists. Here, we assessed aberrant N-glycosylation patterns and alterations in extracellular matrix (ECM) proteins as potential biomarkers of predicting prostate cancer severity in a unique patient outcome cohort. Tissue microarray slides were assembled from primary prostatectomy specimens that were categorized into “no evidence of disease (NED)” and “metastasis (MET)” designations based on >5-year disease progression outcomes. Serial mass spectrometry imaging techniques were performed to analyze N-glycans and ECM components in formalin-fixed paraffin-embedded cores. The results revealed a significant upregulation of bisecting and multiantennary core-fucosylated N-glycans in MET tissues when compared with NED tissues. Alterations in ECM composition in both NED and MET cohorts were observed, particularly in collagen species and the amount of hydroxyproline content. Results suggest a coordinated alteration of ECM protein and glycosylation content in prostate cancer tissues can be predictive for postprostatectomy disease progression. Significance: Using matrix-assisted laser desorption/ionization mass spectrometry imaging techniques on a unique cohort of prostate cancer tissues, we highlighted several molecular characteristics of matrix that have potential to act as early predictors of prostate cancer metastasis.

Year:

2025

Clinical characteristics for each patient in the cohort. There were 51 patients in the “MET” cohort and 73 patients in the “NED” cohort. Data from each patient were collected including age at time of prostatectomy, years of follow up, PSA levels at time of biopsy, race, lymph node status, and tumor margins. Tumor stage and Gleason score information are provided in Supplementary Table S4

Year:

2024

Collagen/ECM imaging data from TMAs comparing metastasis vs. no recurrence. A, Representative MALDI-MSI images of TMAs from metastasis (MET) category and no recurrence (NED) category. B, Segmentation analysis of 294 detected peptides. C, Volcano plot created from list of 294 detected peptides D, Heatmap of top 150 significantly different detected peptides. E, Box plot and ROC curve for 1179.5603 m / z . F, Box plot and ROC curve for 1426.6743 m / z . G, Box plot and ROC curve for 890.4250 m / z .

Year:

2024

Workflow protocols for sample preparation. For N-glycan analysis, FFPE slides were deparaffinized and rehydrated before undergoing antigen retrieval in citraconic buffer. PNGaseF (1) was applied as a “dry” molecular coating before a 2-hour incubation at 37°C. CHCA matrix was applied, and imaging of N-glycans was performed. For analysis of core- vs outer-arm fucosylated N-glycans, enzyme EndoF3 (2) was dialyzed before application, and imaging of EndoF3-digested N-glycans was performed before subsequent PNGaseF digestion and imaging of remaining N-glycans. Following glycan imaging, CHCA matrix was removed from tissues, and samples were histologically analyzed following H&E staining. Tissues underwent a second antigen retrieval with tris buffer before COLaseIII (3) was applied as a “dry” molecular coating. Slides were incubated for 5 hours at 37°C. CHCA matrix was applied, and imaging of collagen/ECM peptides was performed.

Year:

2024

Collagen/ECM MALDI-MSI data from full tissue samples ( A ) H&E-stained images of tissue from metastasis (MET) category and no recurrence (NED) category. Region where TMA was sampled is circled in black. Note that the MET tissue is the same H&E image used in Supplementary Fig. S8A, as N-glycans and collagenase peptides were detected sequentially on the same tissue slide. B, Corresponding MALDI-MSI images after digestion with COLaseIII from the two metastasis (MET) tissues (top) and the two no recurrence (NED) tissues (bottom). Corresponding m / z values for each image are shown to the right. C, Representative MALDI-MSI images from the metastasis (MET) TMA and no recurrence (NED) TMA of the same mass corresponding to full tissues. Note that the collagenase peptide image for m / z = 891.4323 is the same data image used in Fig. 5A for this ion.

Year:

2024

Glycan imaging data from TMA comparing metastasis vs. no recurrence. A, MALDI-MSI images of TMAs from metastasis (MET) category and no recurrence (NED) category. N-glycan images representative of differentiating expression of select N-glycan categories, followed by segmentation analysis of 152 detected N-glycans. B–I, Box plot and ROC curves for each category of N-glycan detected within each group of TMAs. t test results shown on each boxplot.

Year:

2024

Evidence that life-extending interventions are not uniformly effective across the lifespan calls for an analytic tool that can estimate age-specific treatment effects on mortality hazards. Here we report such a tool, applying it to mouse data from 42 compounds tested in the NIA Interventions Testing Program. This tool identified agents that either reduced (22) or increased (15) mortality hazards or did both (2) in at least one sex, most with marked variation in the duration of efficacy and magnitude of effect size. Only 8 reduced mortality hazards after 90% mortality, when the burden of senescence is the greatest. Sex differences were common. This new analytic tool complements the commonly used log-rank test. It detects more potential life-extending candidates (22 versus 10) and indicates when during the life course they are effective. It also uncovers adverse effects.

Year:

2024

Year:

2024

Collaborators (9)

Randy Strong

Professor

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

Robin Leach

Professor

-

UNITED STATES
View details

Lyndsay Young

Research Assistant Professor

Medical University of South Carolina

UNITED STATES
View details

Anand S. Mehta

SmartState Endowed Chair of Proteomic Biomarkers and Professor

Medical University of South Carolina

UNITED STATES
View details

Joseph E Ippolito

Associate Professor

Washington University School of Medicine

UNITED STATES
View details

Lauren Ball

Director, Mass Spectrometry Facility; Associate Professor

Medical University of South Carolina

UNITED STATES
View details

Jennifer Wu

Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Richard Drake

Professor and Endowed Chair in Proteomics

Medical University of South Carolina

UNITED STATES
View details

James Nelson

professor

University of Texas Health Science Center at San Antonio

UNITED STATES
View details